Over 65% of respondents would test individual biomarkers during initial diagnostic workup for stage III NSCLC (EGFR, ALK, ROS1, KRAS, programmed death-ligand 1) (Supplementary Table 2). The gene discussed is KRAS; the disease is non-small cell lung carcinoma.